On December 19, 2024, the U.S. Food and Drug Administration (FDA) announced that the shortage of diabetes and weight-loss tirzepatide injection products has been resolved. This decision, issued through a declaratory order, replaces the agency’s October 2, 2024, determination on the same matter, following a court-mandated reevaluation. In its announ
1969 Reached2 Comments1 Likes
Complicated case of Osteoarthritis
1849 Reached2 Comments3 Likes
Pregnant Woman with HIV-1 Infection
747 Reached1 Likes
Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes
Male with Jaw Pain and Abdominal Bloating
790 Reached24 Comments26 Likes
Case of Adolescent with Severe Macrocytic Anaemia
51074 Reached499 Comments51 Likes